The term incretins is used to denote intestinal hormones released in response to nutrient ingestion that are able to potentiate glucosestimulated insulin secretion. 1, 2 The communication between the intestine and the endocrine pancreas is demonstrated by the observation that the increase of plasma insulin levels following oral glucose administration is much greater than that seen after intravenous glucose. [1] [2] [3] [4] This phenomenon has been termed the 'incretin effect', and accounts for 50-70% of the total insulin secreted after oral glucose. [1] [2] [3] [4] The first incretin hormone to be identified was gastric inhibitory polypeptide (GIP), named because of its ability to reduce gastric acid secretion in dogs. However, this effect is seen at pharmacological doses, whereas the incretin action is observed at physiological levels.
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The hormone was therefore re-named glucose-dependent insulinotropic polypeptide, but retains the acronym GIP.
A second incretin hormone was discovered showing 50% homology with glucagon, and named glucagon-like peptide-1 (GLP-1). Both GLP-1 (mainly from L cells in the distal intestine) and GIP (primarily produced by K cells in the duodenum) are released within minutes following food ingestion and contribute to the rapid disposal of nutrients through several pathways, with the action on the pancreatic β cell probably representing the most important mechanism. [1] [2] [3] [4] Their circulating levels decrease rapidly (the half-life of GLP-1 is approximately two minutes and that of GIP is approximately six minutes) due to enzymatic inactivation by dipeptidyl peptidase-4 (DPP-4). Both GIP and GLP-1 contain alanine at position two, which render them excellent substrates for DPP-4. [1] [2] [3] [4] The pleiotropic actions of incretins on the regulation of blood glucose have led to the concept that GLP-1 and/or GIP could be used in the treatment of type 2 diabetes. In type 2 diabetes GIP action is reduced, whereas its secretion does not seem to be altered. GLP-1 shows a lower insulinotropic effect. Individuals with type 2 diabetes show a small but significant reduction in meal-stimulated levels of GLP-1 and the action of this incretin remains relatively preserved, so most efforts have focused on GLP-1. [2] [3] [4] [5] Two main classes of drug have been developed: GLP-1 receptor agonists resistant to the action of DPP-4 (GLP-1 mimetics) and inhibitors of DDP-4 (GLP-1 enhancers) (see Figure 1) . [2] [3] [4] [5] This article will discuss the effects of GLP-1 and its mimetics on the function of pancreatic islets, particularly in the case of type 2 diabetes.
The Pancreatic Islets in Type 2 Diabetes
Type 2 diabetes is by far the most common form of diabetes, representing approximately 90% of all cases. 6 It results from a combination of genetic and acquired factors that impair β-cell function and tissue insulin sensitivity. 6, 7 Increasing evidence shows that β-cell dysfunction, characterised by decreased β-cell mass and insulin secretion defects, is central to the onset and progression of this disease. [7] [8] [9] In a normal pancreas there are approximately one million islets of Langerhans, which contain several different types of endocrine cell. The insulin-secreting β cells represent the majority of islet endocrine cells (60-80%), followed by glucagon-containing cells (α cells, 20-30%), somatostatin (δ) cells (5-15%) and pancreatic polypeptide (PP) cells. β-cell mass is regulated by four major mechanisms: apoptosis (programmed cell death), size modification (hypo-and hyperplasia), replication (mitotic division of differentiated β cells) and neogenesis (development from precursor cells). [8] [9] [10] The amount of β-cell mass is given by the sum of replication, size and neogenesis, minus the rate of apoptosis. The role of reduced β-cell mass in type 2 diabetes, the primary importance of β-cell apoptosis and the insufficiency of replication/neogenesis have been studied by several authors. Decreased islet mass, reduced β-cell mass and diminished β-cell insulin-secretory granules have been generally reported (see Figure   2 ). [7] [8] [9] [10] A few studies have shown increased α-cell volume in the islets of patients with type 2 diabetes. 11 This leads to alterations of insulin and glucagon secretion in type 2 diabetes. [7] [8] [9] [10] [12] [13] [14] Ugo Boggi is an Associate Professor of Surgery and Head of the Division of General and Transplant Surgery in Uraemic and Diabetic Patients at the University of Pisa. He has performed over 4,000 interventions, covering all fields of general and minimally invasive surgery. His main areas of interest and specialisation are pancreas oncology -he has performed over 400 pancreatectomies -and abdominal organ transplantation -he has performed over 1,000 grafts. As an academic surgeon, Dr Boggi has trained several generations of general and transplant surgeons, and has provided many contributions to the medical literature. He graduated in medicine from the University of Pisa, where he also received most of his surgical training and conducted the majority of his research.
DPP-4 Inhibitors and Incretin Mimetics The Effects of Incretin Mimetics on Islet Cell Function in Type 2 Diabetes
Qualitative defects in insulin release are represented, besides changes of early-phase insulin secretion, by alterations of oscillatory patterns and increased pro-insulin release. Alterations of glucagon secretion in type 2 diabetes include an inappropriately high release in relation to the prevailing glucose levels and increased secretion in response to arginine stimulation compared with non-diabetic subjects. [12] [13] [14] Glucagon-like Peptide-1 Signalling Pathway and the
Pancreatic Islets
Human islets are well equipped with molecules involved in GLP-1 action. With the aim of exploring the potential of GLP-1 receptors as targets in nuclear medicine, Korner et al. investigated the GLP-1 receptor protein qualitatively and quantitatively in a large spectrum of human neoplastic and non-neoplastic tissues. 15 The technique of 125 I-GLP-1 amide receptor autoradiography showed that in the pancreas both islets and acini express GLP-1 receptors, with higher levels in the islets. 15 In a few cases of chronic pancreatitis, islets showed a lower GLP-1 receptor density, but the acinar GLP-1 receptor expression was unchanged. When immunostaining was performed in human pancreatic samples, it was found that GLP-1 receptor positivity was mostly found in β cells and duct cells 16, 17 (see 
Function of Pancreatic Islets
The effects on pancreatic islet cells of acute and prolonged exposure to GLP-1 or insulin mimetics have been studied both in vivo in patients and using isolated human islets of Langerhans. Early work showed that when GLP-1 was infused for a few hours in patients with type 2 diabetes, glucose levels were normalised, insulin and C-peptide concentrations increased significantly and plasma glucagon diminished. 21 When normal glycaemia was reached, insulin and C-peptide returned to basal levels and plasma glucose concentrations remained stable despite the ongoing infusion of GLP-1. 21 This finding is of relevance, as it demonstrates that incretins reduce blood glucose levels without inducing hypoglycaemia.
In an extensive study where GLP-1 was given subcutaneously for six weeks in a group of 20 patients with type 2 diabetes, 22 metabolic control improved significantly compared with that observed following placebo treatment. The hyperglycaemic clamp technique was used to assess features of β-cell function and showed that C-peptide concentrations, first-and second-phase insulin secretion in response to glucose and peak values of C-peptide after arginine stimulation improved significantly with GLP-1 but not with saline treatment (see Figure 4) . 22 Fehse and colleagues studied a group of subjects with type 2 diabetes following short-term exposure to intravenous exenatide. 23 They found that this GLP-1 mimetic could restore the first phase of insulin secretion in response to intravenous glucose in the patients with In vivo studies allow for only the indirect evaluation of pancreatic islet function mainly due to the influences of many additional variables, including, in particular, the degree of insulin sensitivity and the prevailing glucose concentrations. Work has been carried out to assess the direct effects of incretins on human pancreatic islet cells by using isolated islets. Preliminary studies show that in the presence of 10mmol/l glucose, 10nmol/l GLP-1 could significantly potentiate insulin release, leading to a ~30% increase. 27 The potentiating effect was weaker at 2.8mmol/l glucose. In that study, it was also observed that GLP-1 inhibited glucagon secretion and stimulated somatostatin and pancreatic polypeptide release. 27 More extensive studies have been performed. Using islet cell preparations, it was observed that during a two-hour static incubation period, insulin release increased from 3.8±0.9 to 12.6±2.1% of insulin content when glucose concentration in the incubation medium was raised from 2.5 to 10mmol/l. 18 The addition of 10nmol/l glucose GLP-1 in the medium containing 10mmol/l glucose determined a two-fold increase of insulin secretion (which was similar to the effects induced by 10nmol/l GIP or glucagon). 18 Farilla et al. incubated isolated human islets prepared from three independent donors for five days in the presence or absence of 10nmol/l GLP-1 (added every 12 hours), and performed survival, functional and molecular studies. 28 Better preservation of 3D islet morphology was observed in the GLP-1 exposed islets, which was associated with a twoto three-fold decrease in the number of apoptotic islet cells.
Concomitantly, the anti-apoptotic molecule bcl-2 was upregulated and the expression of active caspase-3 (a crucial executor of apoptosis) was suppressed. Glucose-stimulated insulin secretion was also studied.
Exposure to GLP-1 enhanced the capability of the islets to respond to glucose 15mmol/l glucose (no difference was found in response to 6mmol/l glucose). The effect was particularly clear after three days of culture. On day five all culture conditions showed a decrease in glucosedependent insulin secretion. This was less prominent in islets cultured in the presence of GLP-1. These effects were accompanied by increased intracellular insulin content, suggesting that GLP-1 could promote insulin synthesis. 28 In a recently published paper, Lupi et al. obtained isolated human islets from the pancreas of 11 subjects without diabetes and seven individuals with type 2 diabetes of comparable age and body mass index. 20 The islets were then cultured for two days at 5.5mmol/l glucose, either with or without the addition of 10nmol/l exendin-4. At the end of the and cyclin D1 (a molecule involved in the cell cycle) was observed in the islets cultured with exendin-4. 20 Additional evidence that incretins can increase the expression of molecules involved in β-cell differentiation comes from the study performed by Brun et al. on the transcription factor Pax4. 29 The authors found that Pax4 is expressed in human pancreatic islets and was increased in patients with type 2 diabetes with a body mass index below 26kg/m 2 , and long-term adiposity favoured suppression of the gene. 
